ARTICLE | Product Development
Slaoui updates on COVID-19 vaccines, warns about slow enrollment in adolescent trial
January 12, 2021 10:14 PM UTC
If clinical trials yield positive results, Johnson & Johnson’s COVID-19 vaccine could be authorized in the U.S. by mid-February, the Oxford/AstraZeneca vaccine could receive Emergency Use Authorization in late March, and a vaccine from Novavax could be authorized in late April, Moncef Slaoui, scientific adviser and co-leader of Operation Warp Speed said Tuesday.
Correlates of protection that could speed the development of additional COVID-19 vaccines could be validated in the middle of next month, facilitating the development of additional vaccines, he added. ...